Purpose
The homeodomain transcription factor CDX2 is a relatively specific immunohistochemical marker for gastrointestinal carcinoma. However, no study has comprehensively examined the relationship between CDX2 expression in colon cancer and clinical, pathologic, prognostic and molecular features, including microsatellite instability (MSI) and CpG island methylator phenotype (CIMP).
Experimental Design
Utilizing 621 colorectal cancers with clinical outcome and molecular data, CDX2 loss was detected in 183 (29%) tumors by immunohistochemistry.
Results
In multivariate logistic regression analysis, CDX2 loss was associated with female gender [odds ratio (OR)=3.32; p<0.0001], CIMP-high (OR=4.42; p=0.0003), high tumor grade (OR=2.69; p=0.0085), stage IV disease (OR=2.03; p=0.019), and inversely with LINE-1 hypomethylation (for a 30% decline; OR=0.33; p=0.0031), p53 expression (OR=0.55; p=0.011), β-catenin activation (OR=0.60; p=0.037), but not with body mass index, tumor location, MSI, BRAF, KRAS, PIK3CA, p21 or COX-2. CDX2 loss was not independently associated with patient survival. However, the prognostic effect of CDX2 loss appeared to differ according to family history of colorectal cancer (Pinteraction=0.0094). CDX2 loss was associated with high overall mortality [multivariate hazard ratio (HR)=2.40; 95% CI, 1.28–4.51] among patients with a family history of colorectal cancer; no such association was present (multivariate HR=0.97; 95% CI, 0.66–1.41) among patients without a family history of colorectal cancer.
Conclusions
CDX2 loss in colorectal cancer is independently associated with female gender, CIMP-high, high-level LINE-1 methylation, high tumor grade, and advanced stage. CDX2 loss may be associated with poor prognosis among patients with a family history of colorectal cancer.